Genzyme's shareholder solidarity forces Sanofi-Aventis to extend offer
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has extended its tender offer to acquire Genzyme after the biotech's shareholders tendered just 0.9% of the outstanding shares in the initial offer period.